Neurotransmitter transporters are present in nerve terminal membranes and are responsible for the inactivation of released neurotransmitter by reuptake. One such transporter is the serotonin transporter which also represents the site of action of many clinically used tricyclic antidepressants, such as imipramine.
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Recently, most of the known Na+-dependent neurotransmitter transporters have been cloned and sequenced (for review see (I) ). On the basis of sequence similarities, the transporters can be divided into two superfamilies. Within each family many features are conserved which may serve important structural, functional or regulatory roles. One such feature, conserved throughout the superfamily of which the serotonin transporter is a member, is two cysteines, nine amino acids apart, which are located on a putative large extracellular loop of the protein. It has been proposed that these cysteines may be involved in ligand binding and/or substrate uptake by the transporters, or perhaps function in maintaining the transporters in an active conformation (2). Thus, the effects of the sulphydryl reducing agent, dithiothreithol (DTT), on ligand binding to the human platelet serotonin transporter were studied.
When the binding of the tricyclic antidepressant, [3H]imipramine, to human platelet membranes was measured over a range of increasing DTT concentrations, a concentration dependent increase in [3H] imipramine binding was found with maximum binding being achieved at a DTT concentration of 5 mM. Saturation studies were performed, incubating platelet membranes with a range of [3H]imipramine concentrations in the presence of DTT. Analysis of the saturation curves revealed a 2 to 3 fold decrease in the apparent KD value for [3H]imipramine binding to membranes in the presence of DTT, relative to the control value determined in the absence of DTT. This DTT induced decrease in the KD value was B, , , values were unaffected by the presence of DTT (Table 1) .
The kinetic basis of this DTT induced increase in affinity of the platelet membranes for [3H]imipramine was also studied via dilution-induced dissociation experiments, as described previously (3). Human platelet membranes and [3H]imipramine were incubated in the presence of 10 mM DTT and diluted 50-fold into assay buffer containing 10 mM DTT. A slowing of the rate of dissociation of [3H]imipramine from the membranes was observed relative to the control experiment, which was carried out in the absence of DTT. The dissociation curve was biphasic in the absence of DTT while in the presence of DTT the curve was either monophasic (slowly dissociating) or tended towards this condition (Fig.1.) Ci/mmol) binding to unsolubilized and solubilized human platelet membranes were performed (as described in Fig.l.) , in the presence and absence of 5 mM DTT, at 4oC. Digitonin solubilized membranes were prepared as described previously (3, using the following solubilization buffer 50 mM Tris/HCI, pH 7.4, containing 5 mM KC1, 2 mM MgCIzand 1 mM EDTA. KD and B,,, values were determined by fitting the data to a rectangular hyperbola by weighted non-linear regression (5). The results shown are typical values from t hree or more exueriments . biphasic condition towards the monophasic state. The effect appeared maximal at 5 mM DTT and no further slowing of the dissociation rate was achieved at higher D l T concentrations. When dilution-induced dissociation of [3H]imipramine from platelet membranes is carried out in the presence of the transporter substrate, serotonin (0.5 mM), a similar slowing of the [3H]imipramine dissociation rate is observed. This observation is consistent with previously published studies (3) and indicates that both serotonin and DTT induce similar conformational changes in the transporter structure. Further evidence for a DTT-induced conformational change in transporter structure is provided by heatinactivation studies. Platelet membranes and [3H]imipramine were incubated in the presence and absence of DTT (5mM) at 60°C. Biphasic heat-inactivation curves were obtained in the absence of DTT while curves approaching a monophasic (rapidly inactivated) condition were obtained in the presence of DTT. This indicates that the conformation of the transporter in its thiol-reduced form is more sensitive to heat-denaturation.
The experiments described above were repeated using the nontricyclic antidepressant, [3H]paroxetine, as a ligand for the serotonin transporter. DTT had no detectable effect on the affinity of [3H]paroxetine for the transporter.
These results demonstrate that the transporter exists in two conformational states in vitro which are determined by thiol oxidation status. This may be crucial in regulation of the structure and function of the transporter by its substrate, serotonin. 5. Leatherbarrow, R.J. (1988) in The ENZFITTJ3R Manual, Elsevier-Biosoft, Cambridge.
